Zelgen's PD-1/TIGIT Bispecific Antibody Nilvanstomig Demonstrates Promising Phase II Efficacy in First-Line Advanced Hepatocellular Carcinoma at ASCO 2026
May 25, 2026 16:11
CST Updated
May 26, 03:12
Zelgen
Innovative Drug Research and Development, Manufacturer